LCTX

#2786
Lineage Cell Therapeutics, Inc. Common Stock
1.3 4 USD
+9900.00%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
1.34
1.35
Rango anual
0.01
1.98
Cambio diario
+9900.00%
Variación mensual
-10.65%
Variación en los últimos 6 meses
-21.96%
Cambio anual
-21.96%
Cierres anteriores
0.0 1
Open
1.3 5
Mínimo
1.3 4
High
1.3 5
Volumen
19
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 202020212022202320242025 TTM

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

Noticias